Efficacy and toxicity of KRASG12C inhibitors in advanced solid tumors: a meta-analysis
Background The efficacy and toxicity of KRAS.sup.G12C inhibitors were evaluated for advanced solid tumors in several studies; however, the results were not fully consistent. Methods Clinical trials evaluating KRAS.sup.G12C inhibitors for advanced solid tumors were searched from PubMed, Embase, and C...
Saved in:
| Published in | World journal of surgical oncology Vol. 22; no. 1; pp. 182 - 12 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
BioMed Central Ltd
16.07.2024
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Background The efficacy and toxicity of KRAS.sup.G12C inhibitors were evaluated for advanced solid tumors in several studies; however, the results were not fully consistent. Methods Clinical trials evaluating KRAS.sup.G12C inhibitors for advanced solid tumors were searched from PubMed, Embase, and Cochrane Library online databases up to 31st December 2023. The characteristics of the studies and the results of objective response rate (ORR), disease control rate (DCR), duration of response (DoR), progression-free survival (PFS) rate, overall survival (OS) rate, and treatment-related adverse events (trAEs) were extracted. Results Ten studies with 925 heavily pretreated advanced patients harboring KRAS.sup.G12C mutation were included. For total population, the pooled analysis of ORR was 28.6% (95%CI, 21.2-36.6%), DCR was 85.5% (95%CI, 82.2-88.6%), PFS rate at 6 months (PFS6) was 49.6% (95%CI, 41.4-57.9%), PFS rate at 12 months (PFS12) was 26.7% (95%CI, 19.8-34.1%), OS rates at 6 months (OS6) was 76.2% (95%CI, 68.8-82.9%), OS rates at 12 months (OS12) was 47.8% (95%CI, 38.6-57.0%). The pooled analysis of any grade trAEs was 79.3% (95%CI, 66.2-90.0%) and grade three or more trAEs was 24.4% (95%CI, 16.7-32.9%). The median time to response and DoR results from individual data were 1.39 months (95%CI, 1.37-1.41 months) and 10.54 months (95%CI, 7.72-13.36 months). Sotorasib had significantly lower pooled incidences of any trAEs (OR, 0.07, 95%CI, 0.03-0.14) and grade three or more trAES (OR, 0.34, 95%CI, 0.24-0.49) compared with adagrasib. Conclusions KRAS.sup.G12C inhibitors have good ORR, DCR, PFS rate, OS rate, tolerable trAEs, and early response with long duration in advanced solid tumors; however, most of the pooled results were heterogeneous. Sotorasib has shown better safety results. Keywords: KRAS.sup.G12C inhibitors, Solid tumors, Meta-analysis |
|---|---|
| AbstractList | The efficacy and toxicity of KRASG12C inhibitors were evaluated for advanced solid tumors in several studies; however, the results were not fully consistent.BACKGROUNDThe efficacy and toxicity of KRASG12C inhibitors were evaluated for advanced solid tumors in several studies; however, the results were not fully consistent.Clinical trials evaluating KRASG12C inhibitors for advanced solid tumors were searched from PubMed, Embase, and Cochrane Library online databases up to 31st December 2023. The characteristics of the studies and the results of objective response rate (ORR), disease control rate (DCR), duration of response (DoR), progression-free survival (PFS) rate, overall survival (OS) rate, and treatment-related adverse events (trAEs) were extracted.METHODSClinical trials evaluating KRASG12C inhibitors for advanced solid tumors were searched from PubMed, Embase, and Cochrane Library online databases up to 31st December 2023. The characteristics of the studies and the results of objective response rate (ORR), disease control rate (DCR), duration of response (DoR), progression-free survival (PFS) rate, overall survival (OS) rate, and treatment-related adverse events (trAEs) were extracted.Ten studies with 925 heavily pretreated advanced patients harboring KRASG12C mutation were included. For total population, the pooled analysis of ORR was 28.6% (95%CI, 21.2-36.6%), DCR was 85.5% (95%CI, 82.2-88.6%), PFS rate at 6 months (PFS6) was 49.6% (95%CI, 41.4-57.9%), PFS rate at 12 months (PFS12) was 26.7% (95%CI, 19.8-34.1%), OS rates at 6 months (OS6) was 76.2% (95%CI, 68.8-82.9%), OS rates at 12 months (OS12) was 47.8% (95%CI, 38.6-57.0%). The pooled analysis of any grade trAEs was 79.3% (95%CI, 66.2-90.0%) and grade three or more trAEs was 24.4% (95%CI, 16.7-32.9%). The median time to response and DoR results from individual data were 1.39 months (95%CI, 1.37-1.41 months) and 10.54 months (95%CI, 7.72-13.36 months). Sotorasib had significantly lower pooled incidences of any trAEs (OR, 0.07, 95%CI, 0.03-0.14) and grade three or more trAES (OR, 0.34, 95%CI, 0.24-0.49) compared with adagrasib.RESULTSTen studies with 925 heavily pretreated advanced patients harboring KRASG12C mutation were included. For total population, the pooled analysis of ORR was 28.6% (95%CI, 21.2-36.6%), DCR was 85.5% (95%CI, 82.2-88.6%), PFS rate at 6 months (PFS6) was 49.6% (95%CI, 41.4-57.9%), PFS rate at 12 months (PFS12) was 26.7% (95%CI, 19.8-34.1%), OS rates at 6 months (OS6) was 76.2% (95%CI, 68.8-82.9%), OS rates at 12 months (OS12) was 47.8% (95%CI, 38.6-57.0%). The pooled analysis of any grade trAEs was 79.3% (95%CI, 66.2-90.0%) and grade three or more trAEs was 24.4% (95%CI, 16.7-32.9%). The median time to response and DoR results from individual data were 1.39 months (95%CI, 1.37-1.41 months) and 10.54 months (95%CI, 7.72-13.36 months). Sotorasib had significantly lower pooled incidences of any trAEs (OR, 0.07, 95%CI, 0.03-0.14) and grade three or more trAES (OR, 0.34, 95%CI, 0.24-0.49) compared with adagrasib.KRASG12C inhibitors have good ORR, DCR, PFS rate, OS rate, tolerable trAEs, and early response with long duration in advanced solid tumors; however, most of the pooled results were heterogeneous. Sotorasib has shown better safety results.CONCLUSIONSKRASG12C inhibitors have good ORR, DCR, PFS rate, OS rate, tolerable trAEs, and early response with long duration in advanced solid tumors; however, most of the pooled results were heterogeneous. Sotorasib has shown better safety results. Background The efficacy and toxicity of KRAS.sup.G12C inhibitors were evaluated for advanced solid tumors in several studies; however, the results were not fully consistent. Methods Clinical trials evaluating KRAS.sup.G12C inhibitors for advanced solid tumors were searched from PubMed, Embase, and Cochrane Library online databases up to 31st December 2023. The characteristics of the studies and the results of objective response rate (ORR), disease control rate (DCR), duration of response (DoR), progression-free survival (PFS) rate, overall survival (OS) rate, and treatment-related adverse events (trAEs) were extracted. Results Ten studies with 925 heavily pretreated advanced patients harboring KRAS.sup.G12C mutation were included. For total population, the pooled analysis of ORR was 28.6% (95%CI, 21.2-36.6%), DCR was 85.5% (95%CI, 82.2-88.6%), PFS rate at 6 months (PFS6) was 49.6% (95%CI, 41.4-57.9%), PFS rate at 12 months (PFS12) was 26.7% (95%CI, 19.8-34.1%), OS rates at 6 months (OS6) was 76.2% (95%CI, 68.8-82.9%), OS rates at 12 months (OS12) was 47.8% (95%CI, 38.6-57.0%). The pooled analysis of any grade trAEs was 79.3% (95%CI, 66.2-90.0%) and grade three or more trAEs was 24.4% (95%CI, 16.7-32.9%). The median time to response and DoR results from individual data were 1.39 months (95%CI, 1.37-1.41 months) and 10.54 months (95%CI, 7.72-13.36 months). Sotorasib had significantly lower pooled incidences of any trAEs (OR, 0.07, 95%CI, 0.03-0.14) and grade three or more trAES (OR, 0.34, 95%CI, 0.24-0.49) compared with adagrasib. Conclusions KRAS.sup.G12C inhibitors have good ORR, DCR, PFS rate, OS rate, tolerable trAEs, and early response with long duration in advanced solid tumors; however, most of the pooled results were heterogeneous. Sotorasib has shown better safety results. Keywords: KRAS.sup.G12C inhibitors, Solid tumors, Meta-analysis Abstract Background The efficacy and toxicity of KRASG12C inhibitors were evaluated for advanced solid tumors in several studies; however, the results were not fully consistent. Methods Clinical trials evaluating KRASG12C inhibitors for advanced solid tumors were searched from PubMed, Embase, and Cochrane Library online databases up to 31st December 2023. The characteristics of the studies and the results of objective response rate (ORR), disease control rate (DCR), duration of response (DoR), progression-free survival (PFS) rate, overall survival (OS) rate, and treatment-related adverse events (trAEs) were extracted. Results Ten studies with 925 heavily pretreated advanced patients harboring KRASG12C mutation were included. For total population, the pooled analysis of ORR was 28.6% (95%CI, 21.2-36.6%), DCR was 85.5% (95%CI, 82.2-88.6%), PFS rate at 6 months (PFS6) was 49.6% (95%CI, 41.4-57.9%), PFS rate at 12 months (PFS12) was 26.7% (95%CI, 19.8-34.1%), OS rates at 6 months (OS6) was 76.2% (95%CI, 68.8-82.9%), OS rates at 12 months (OS12) was 47.8% (95%CI, 38.6-57.0%). The pooled analysis of any grade trAEs was 79.3% (95%CI, 66.2-90.0%) and grade three or more trAEs was 24.4% (95%CI, 16.7-32.9%). The median time to response and DoR results from individual data were 1.39 months (95%CI, 1.37–1.41 months) and 10.54 months (95%CI, 7.72–13.36 months). Sotorasib had significantly lower pooled incidences of any trAEs (OR, 0.07, 95%CI, 0.03–0.14) and grade three or more trAES (OR, 0.34, 95%CI, 0.24–0.49) compared with adagrasib. Conclusions KRASG12C inhibitors have good ORR, DCR, PFS rate, OS rate, tolerable trAEs, and early response with long duration in advanced solid tumors; however, most of the pooled results were heterogeneous. Sotorasib has shown better safety results. The efficacy and toxicity of KRAS.sup.G12C inhibitors were evaluated for advanced solid tumors in several studies; however, the results were not fully consistent. Clinical trials evaluating KRAS.sup.G12C inhibitors for advanced solid tumors were searched from PubMed, Embase, and Cochrane Library online databases up to 31st December 2023. The characteristics of the studies and the results of objective response rate (ORR), disease control rate (DCR), duration of response (DoR), progression-free survival (PFS) rate, overall survival (OS) rate, and treatment-related adverse events (trAEs) were extracted. Ten studies with 925 heavily pretreated advanced patients harboring KRAS.sup.G12C mutation were included. For total population, the pooled analysis of ORR was 28.6% (95%CI, 21.2-36.6%), DCR was 85.5% (95%CI, 82.2-88.6%), PFS rate at 6 months (PFS6) was 49.6% (95%CI, 41.4-57.9%), PFS rate at 12 months (PFS12) was 26.7% (95%CI, 19.8-34.1%), OS rates at 6 months (OS6) was 76.2% (95%CI, 68.8-82.9%), OS rates at 12 months (OS12) was 47.8% (95%CI, 38.6-57.0%). The pooled analysis of any grade trAEs was 79.3% (95%CI, 66.2-90.0%) and grade three or more trAEs was 24.4% (95%CI, 16.7-32.9%). The median time to response and DoR results from individual data were 1.39 months (95%CI, 1.37-1.41 months) and 10.54 months (95%CI, 7.72-13.36 months). Sotorasib had significantly lower pooled incidences of any trAEs (OR, 0.07, 95%CI, 0.03-0.14) and grade three or more trAES (OR, 0.34, 95%CI, 0.24-0.49) compared with adagrasib. KRAS.sup.G12C inhibitors have good ORR, DCR, PFS rate, OS rate, tolerable trAEs, and early response with long duration in advanced solid tumors; however, most of the pooled results were heterogeneous. Sotorasib has shown better safety results. |
| ArticleNumber | 182 |
| Audience | Academic |
| Author | Li, Wei Zhao, Jingyang Zhang, Shuyang Dang, Shoutao |
| Author_xml | – sequence: 1 givenname: Shoutao surname: Dang fullname: Dang, Shoutao – sequence: 2 givenname: Shuyang surname: Zhang fullname: Zhang, Shuyang – sequence: 3 givenname: Jingyang surname: Zhao fullname: Zhao, Jingyang – sequence: 4 givenname: Wei surname: Li fullname: Li, Wei |
| BookMark | eNp9kltrFDEYhgep2IP-Aa8GBPFmak4zSbyRZam1WBA83YZvcthNmUnqJFvcf2-mU6QrIrnIl-R9H5J872l1FGKwVfUSo3OMRfc2YSJb3iDCGkQZk414Up1gxnnDBZZHj-rj6jSlG4QIpS19Vh1TiXBZkZPqx4VzXoPe1xBMneMvr33e19HVn76svl5isq592Pre5zilUtZg7iBoa-oUB18cu7EcvKuhHm2GBgIM--TT8-qpgyHZFw_zWfX9w8W39cfm-vPl1Xp13WjGWW5oTwQgoo3VvZOdk9Sx1hnemw5YK4yWFHXcWGy61nCHdId1j21nmOuJ7QQ9q64Wrolwo24nP8K0VxG8ut-I00bBlL0erOKGtD0I3kpJmEasL1SnJZeiADVhhfV-Yd3u-tEabUOeYDiAHp4Ev1WbeKcwJi1GkhfCmwfCFH_ubMpq9EnbYYBg4y4pikRpGe4YKdJXi3QD5W4-uFiQeparlUCYiZaRWXX-D1UZxo5elzQ4X_YPDK8fGbYWhrwtjdplH0M6FJJFqKeY0mTdn3dipOZ0qSVdqqRL3adLzb8t_jKVsMDMLtfyw_-svwExzNL7 |
| CitedBy_id | crossref_primary_10_1007_s11523_024_01107_3 |
| Cites_doi | 10.1056/NEJMoa2105281 10.1056/NEJMoa2308795 10.1016/j.ctrv.2020.101974 10.1056/NEJMoa2212419 10.1200/JCO.2015.63.9674 10.1038/s41586-019-1694-1 10.1056/NEJMoa2103695 10.1016/S1470-2045(21)00605-7 10.1038/35074129 10.1136/bmj.n71 10.1016/j.cell.2018.01.006 10.3390/cancers15235582 10.1021/acs.jmedchem.9b01180 10.1056/NEJMoa2208470 10.1200/JCO.21.02752 10.21873/anticanres.15186 10.1093/annonc/mdu378 10.1016/j.phrs.2024.107060 10.1056/NEJMoa2303810 10.1056/NEJMoa1917239 10.1016/j.jtho.2023.03.015 10.3892/mco.2021.2255 10.3390/cancers14030850 10.3390/jcm12020709 10.1016/S0140-6736(23)00221-0 10.1038/nrd4389 10.3389/fimmu.2023.1223433 10.1016/j.semcancer.2019.06.007 10.1056/NEJMoa2204619 10.1046/j.1445-2197.2003.02748.x |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2024 BioMed Central Ltd. 2024. The Author(s). The Author(s) 2024 2024 |
| Copyright_xml | – notice: COPYRIGHT 2024 BioMed Central Ltd. – notice: 2024. The Author(s). – notice: The Author(s) 2024 2024 |
| DBID | AAYXX CITATION 7X8 5PM DOA |
| DOI | 10.1186/s12957-024-03449-8 |
| DatabaseName | CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1477-7819 |
| EndPage | 12 |
| ExternalDocumentID | oai_doaj_org_article_7d25ba8759924c04be1dfc97981e6c24 PMC11251097 A801485422 10_1186_s12957_024_03449_8 |
| GeographicLocations | China |
| GeographicLocations_xml | – name: China |
| GroupedDBID | --- 0R~ 29R 2WC 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACIWK ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EBD EBLON EBS ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK IAO IHR IHW INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SMD SOJ TR2 TUS UKHRP W2D WOQ WOW XSB ~8M PMFND 7X8 PPXIY 5PM PJZUB PUEGO |
| ID | FETCH-LOGICAL-c474t-3b28a02cdecbf96f93f45fd7bd6a458dc93067de1d65d7f0c61cb1e6d4fb2e683 |
| IEDL.DBID | M48 |
| ISSN | 1477-7819 |
| IngestDate | Wed Aug 27 01:31:57 EDT 2025 Thu Aug 21 18:33:07 EDT 2025 Fri Jul 11 06:21:24 EDT 2025 Tue Jun 17 22:07:27 EDT 2025 Tue Jun 10 21:06:34 EDT 2025 Thu May 22 21:24:45 EDT 2025 Thu Apr 24 23:07:04 EDT 2025 Tue Jul 01 02:21:40 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c474t-3b28a02cdecbf96f93f45fd7bd6a458dc93067de1d65d7f0c61cb1e6d4fb2e683 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12957-024-03449-8 |
| PMID | 39010022 |
| PQID | 3081291642 |
| PQPubID | 23479 |
| PageCount | 12 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_7d25ba8759924c04be1dfc97981e6c24 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11251097 proquest_miscellaneous_3081291642 gale_infotracmisc_A801485422 gale_infotracacademiconefile_A801485422 gale_healthsolutions_A801485422 crossref_primary_10_1186_s12957_024_03449_8 crossref_citationtrail_10_1186_s12957_024_03449_8 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-07-16 |
| PublicationDateYYYYMMDD | 2024-07-16 |
| PublicationDate_xml | – month: 07 year: 2024 text: 2024-07-16 day: 16 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London |
| PublicationTitle | World journal of surgical oncology |
| PublicationYear | 2024 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | BA Lanman (3449_CR10) 2020; 63 MG Fakih (3449_CR14) 2022; 23 F Skoulidis (3449_CR12) 2021; 384 AD Cox (3449_CR5) 2014; 13 MJ Page (3449_CR21) 2021; 372 MR Janes (3449_CR8) 2018; 172 JH Strickler (3449_CR13) 2023; 388 QA Chen (3449_CR26) 2024; 200 K Slim (3449_CR22) 2003; 73 DS Hong (3449_CR11) 2020; 383 L Johnson (3449_CR3) 2001; 410 AJ de Langen (3449_CR15) 2023; 401 3449_CR1 SI Ou (3449_CR18) 2022; 40 3449_CR6 PA Jänne (3449_CR16) 2022; 387 AK Murugan (3449_CR2) 2019; 59 3449_CR23 CJ Allegra (3449_CR30) 2016; 34 M Díez-Alonso (3449_CR25) 2021; 14 SS Zhang (3449_CR27) 2023; 14 R Yaeger (3449_CR20) 2023; 388 M Nagasaka (3449_CR9) 2020; 84 A Sacher (3449_CR19) 2023; 389 Z Li (3449_CR17) 2023; 18 MM Awad (3449_CR31) 2021; 384 MJ Sorich (3449_CR29) 2015; 26 J Canon (3449_CR7) 2019; 575 X Wu (3449_CR4) 2023; 14 MG Fakih (3449_CR28) 2023; 389 T Sato (3449_CR24) 2021; 41 |
| References_xml | – volume: 384 start-page: 2382 issue: 25 year: 2021 ident: 3449_CR31 publication-title: N Engl J Med doi: 10.1056/NEJMoa2105281 – volume: 389 start-page: 2125 issue: 23 year: 2023 ident: 3449_CR28 publication-title: N Engl J Med doi: 10.1056/NEJMoa2308795 – volume: 84 start-page: 101974 year: 2020 ident: 3449_CR9 publication-title: Cancer Treat Rev doi: 10.1016/j.ctrv.2020.101974 – volume: 388 start-page: 44 issue: 1 year: 2023 ident: 3449_CR20 publication-title: N Engl J Med doi: 10.1056/NEJMoa2212419 – volume: 34 start-page: 179 issue: 2 year: 2016 ident: 3449_CR30 publication-title: J Clin Oncol doi: 10.1200/JCO.2015.63.9674 – volume: 575 start-page: 217 issue: 7781 year: 2019 ident: 3449_CR7 publication-title: Nature doi: 10.1038/s41586-019-1694-1 – volume: 384 start-page: 2371 issue: 25 year: 2021 ident: 3449_CR12 publication-title: N Engl J Med doi: 10.1056/NEJMoa2103695 – volume: 23 start-page: 115 issue: 1 year: 2022 ident: 3449_CR14 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(21)00605-7 – volume: 410 start-page: 1111 issue: 6832 year: 2001 ident: 3449_CR3 publication-title: Nature doi: 10.1038/35074129 – volume: 372 start-page: n71 year: 2021 ident: 3449_CR21 publication-title: BMJ doi: 10.1136/bmj.n71 – volume: 172 start-page: 578 issue: 3 year: 2018 ident: 3449_CR8 publication-title: Cell doi: 10.1016/j.cell.2018.01.006 – ident: 3449_CR1 doi: 10.3390/cancers15235582 – volume: 63 start-page: 52 issue: 1 year: 2020 ident: 3449_CR10 publication-title: J Med Chem doi: 10.1021/acs.jmedchem.9b01180 – volume: 388 start-page: 33 issue: 1 year: 2023 ident: 3449_CR13 publication-title: N Engl J Med doi: 10.1056/NEJMoa2208470 – volume: 40 start-page: 2530 issue: 23 year: 2022 ident: 3449_CR18 publication-title: J Clin Oncol doi: 10.1200/JCO.21.02752 – volume: 41 start-page: 3905 issue: 8 year: 2021 ident: 3449_CR24 publication-title: Anticancer Res doi: 10.21873/anticanres.15186 – volume: 26 start-page: 13 issue: 1 year: 2015 ident: 3449_CR29 publication-title: Ann Oncol doi: 10.1093/annonc/mdu378 – volume: 200 start-page: 107060 year: 2024 ident: 3449_CR26 publication-title: Pharmacol Res doi: 10.1016/j.phrs.2024.107060 – volume: 389 start-page: 710 issue: 8 year: 2023 ident: 3449_CR19 publication-title: N Engl J Med doi: 10.1056/NEJMoa2303810 – volume: 383 start-page: 1207 issue: 13 year: 2020 ident: 3449_CR11 publication-title: N Engl J Med doi: 10.1056/NEJMoa1917239 – volume: 18 start-page: 940 issue: 7 year: 2023 ident: 3449_CR17 publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2023.03.015 – volume: 14 start-page: 93 issue: 5 year: 2021 ident: 3449_CR25 publication-title: Mol Clin Oncol doi: 10.3892/mco.2021.2255 – ident: 3449_CR23 doi: 10.3390/cancers14030850 – ident: 3449_CR6 doi: 10.3390/jcm12020709 – volume: 401 start-page: 733 issue: 10378 year: 2023 ident: 3449_CR15 publication-title: Lancet doi: 10.1016/S0140-6736(23)00221-0 – volume: 13 start-page: 828 issue: 11 year: 2014 ident: 3449_CR5 publication-title: Nat Rev Drug Discov doi: 10.1038/nrd4389 – volume: 14 start-page: 1223433 year: 2023 ident: 3449_CR4 publication-title: Front Immunol doi: 10.3389/fimmu.2023.1223433 – volume: 59 start-page: 23 year: 2019 ident: 3449_CR2 publication-title: Semin Cancer Biol doi: 10.1016/j.semcancer.2019.06.007 – volume: 387 start-page: 120 issue: 2 year: 2022 ident: 3449_CR16 publication-title: N Engl J Med doi: 10.1056/NEJMoa2204619 – volume: 73 start-page: 712 issue: 9 year: 2003 ident: 3449_CR22 publication-title: ANZ J Surg doi: 10.1046/j.1445-2197.2003.02748.x – volume: 14 start-page: 27 year: 2023 ident: 3449_CR27 publication-title: Lung Cancer (Auckl) |
| SSID | ssj0023353 |
| Score | 2.3642023 |
| Snippet | Background The efficacy and toxicity of KRAS.sup.G12C inhibitors were evaluated for advanced solid tumors in several studies; however, the results were not... The efficacy and toxicity of KRAS.sup.G12C inhibitors were evaluated for advanced solid tumors in several studies; however, the results were not fully... The efficacy and toxicity of KRASG12C inhibitors were evaluated for advanced solid tumors in several studies; however, the results were not fully... Abstract Background The efficacy and toxicity of KRASG12C inhibitors were evaluated for advanced solid tumors in several studies; however, the results were not... |
| SourceID | doaj pubmedcentral proquest gale crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database |
| StartPage | 182 |
| SubjectTerms | Analysis Cancer Care and treatment Complications and side effects Enzyme inhibitors KRASG12C inhibitors Medical research Medicine, Experimental Meta-analysis Online databases Panitumumab Physiological aspects Solid tumors Testing Tumors |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NaxUxEA_Sg3gR6wc-rW0EwYOE7mbz2dtraS1KPaiV3kI-6YLdJ3YftP-9k-zuo6ugF2_LzgQ2v8zszJDkNwi9YcFVQTaUWOc4FCheECeVJoKCecUmhETzbeSzT-L0nH244Bd3Wn3lM2EDPfAA3L4MlDsLWbWGSsFXzMU6JK-lVnUUnhYmUIh5UzE1llpNw5vpiowS-9cQ1bgkEI9IprjTRM3CUGHr__Of_Ps5yTuB5-QRejhmjHg5fOk2uhe7x-j-2bgn_gR9O84sENbfYtsF3K9u4H1_i1cJf_y8_PK-pke47S5b1-a-OvCIp21_DGbXwoj1FQgOsMVXsbfEjiwlT9H5yfHXo1MydksgnknWk8ZRZSvqQ_QuaZF0kxhPQbogLOMqeJ2rgwDwCR5kglWpvQMMA0uORqGaZ2irW3XxOcLMSlGBI1snE4Oy1QkalY46OMurpOkC1RN4xo9U4rmjxXdTSgolzAC4AcBNAdyoBXq3GfNjINL4q_ZhXpONZibBLi_ANMxoGuZfprFAe3lFzXCjdOPKZpkZcxRnFCbytmhkZ4YJwFoNdxIAhkyLNdPcmWmCE_qZ-PVkNSaL8sm1Lq7W16aBnItCDs5AR83MaTa5uaRrLwvTd53Tz0rLF_8DjpfoAS0eIEktdtBW_3MdX0FG1bvd4jy_AOujHHo priority: 102 providerName: Directory of Open Access Journals |
| Title | Efficacy and toxicity of KRASG12C inhibitors in advanced solid tumors: a meta-analysis |
| URI | https://www.proquest.com/docview/3081291642 https://pubmed.ncbi.nlm.nih.gov/PMC11251097 https://doaj.org/article/7d25ba8759924c04be1dfc97981e6c24 |
| Volume | 22 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3rixMxEA_3APGL-MTqWVcQ_CDR3Ww2D0GkPXoeSg-pVopfQl7rLdxttd3C9b93km6Lq4f4ZVmSSWAmMzszm-Q3CD2nzqSO5wRrYwpIUCzDhguJGQH18rlzJQm3kcdn7HRKP8yK2R7aljtqBbi8NrUL9aSmi4tXVz_X78Dg30aDF-z1EnxWwTF4GxwA7CQW--gQPBMPFQ3GdLerQPI8olJmlHPMwRVuL9FcO0fHUUU8_7-_2n-epPzNNZ3cRrfamDIZbJTgDtrz9V10Y9zumt9DX0cBJ0LbdaJrlzTzK2hv1sm8TD5OBp_fZ-Q4qerzylSh8g68JtuDAQkoZgUjVpfQ8SbRyaVvNNYtjsl9ND0ZfTk-xW09BWwppw3ODRE6JdZ5a0rJSpmXtCgdN45pWghnZcgfnM8cKxwvYd0yazLPHC0N8UzkD9BBPa_9Q5RQzVkKpq4NLykktoYRL6SXzugiLSXpoWwrPGVbsPFQ8-JCxaRDMLURuAKBqyhwJXro5W7Mjw3Uxj-ph2FNdpQBJjs2zBffVWt1ijtSGA0pmYQ006bUAG-llVwKYMsS2kNPw4qqzZ3TnbGrQcDUEQUlwMiLSBEUEBiAtdrcWgAxBOCsDuVRhxLM1Ha6n221RoWucLat9vPVUuUQlRGI0inQiI46dZjr9tTVecQCz0KAmkr-6D-mf4xukqjgHGfsCB00i5V_AiFVY_pon894Hx0OR2efJv34Y6IfbQeek-G3X5XLH8o |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Efficacy+and+toxicity+of+KRASG12C+inhibitors+in+advanced+solid+tumors%3A+a+meta-analysis&rft.jtitle=World+journal+of+surgical+oncology&rft.au=Dang%2C+Shoutao&rft.au=Zhang%2C+Shuyang&rft.au=Zhao%2C+Jingyang&rft.au=Li%2C+Wei&rft.date=2024-07-16&rft.issn=1477-7819&rft.eissn=1477-7819&rft.volume=22&rft.issue=1&rft.spage=182&rft_id=info:doi/10.1186%2Fs12957-024-03449-8&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1477-7819&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1477-7819&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1477-7819&client=summon |